AMARIN CORP PLC -ADR (AMRN) Fundamental Analysis & Valuation

NASDAQ:AMRN • US0231114044

14.06 USD
-0.12 (-0.85%)
At close: Mar 6, 2026
14.06 USD
0 (0%)
After Hours: 3/6/2026, 8:00:39 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AMRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AMRN. AMRN was compared to 520 industry peers in the Biotechnology industry. AMRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AMRN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. AMRN Profitability Analysis

1.1 Basic Checks

  • In the past year AMRN has reported negative net income.
  • AMRN had a negative operating cash flow in the past year.
  • In the past 5 years AMRN reported 4 times negative net income.
  • AMRN had negative operating cash flow in 4 of the past 5 years.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • AMRN has a better Return On Assets (-13.12%) than 81.35% of its industry peers.
  • AMRN has a Return On Equity of -18.87%. This is amongst the best in the industry. AMRN outperforms 83.46% of its industry peers.
Industry RankSector Rank
ROA -13.12%
ROE -18.87%
ROIC N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

  • AMRN's Gross Margin of 54.96% is fine compared to the rest of the industry. AMRN outperforms 77.12% of its industry peers.
  • AMRN's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for AMRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AMRN Health Analysis

2.1 Basic Checks

  • AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • AMRN has an Altman-Z score of -1.73. This is a bad value and indicates that AMRN is not financially healthy and even has some risk of bankruptcy.
  • AMRN's Altman-Z score of -1.73 is in line compared to the rest of the industry. AMRN outperforms 52.12% of its industry peers.
  • AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.73
ROIC/WACCN/A
WACC7.7%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • AMRN has a Current Ratio of 3.45. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
  • AMRN has a Current ratio of 3.45. This is comparable to the rest of the industry: AMRN outperforms 41.54% of its industry peers.
  • A Quick Ratio of 2.43 indicates that AMRN has no problem at all paying its short term obligations.
  • AMRN has a worse Quick ratio (2.43) than 69.23% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 2.43
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMRN Growth Analysis

3.1 Past

  • AMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.55%, which is quite impressive.
EPS 1Y (TTM)99.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-21%

3.2 Future

  • AMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 142.35% yearly.
  • Based on estimates for the next years, AMRN will show a very strong growth in Revenue. The Revenue will grow by 27.58% on average per year.
EPS Next Y-104%
EPS Next 2Y-74.93%
EPS Next 3Y385.16%
EPS Next 5Y142.35%
Revenue Next Year-19.33%
Revenue Next 2Y-11.01%
Revenue Next 3Y-2.88%
Revenue Next 5Y27.58%

3.3 Evolution

AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. AMRN Valuation Analysis

4.1 Price/Earnings Ratio

  • AMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AMRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • AMRN's earnings are expected to grow with 385.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-74.93%
EPS Next 3Y385.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMRN Dividend Analysis

5.1 Amount

  • No dividends for AMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMRN Fundamentals: All Metrics, Ratios and Statistics

AMARIN CORP PLC -ADR

NASDAQ:AMRN (3/6/2026, 8:00:39 PM)

After market: 14.06 0 (0%)

14.06

-0.12 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners20.09%
Inst Owner Change-18.39%
Ins Owners0.81%
Ins Owner Change0.22%
Market Cap292.35M
Revenue(TTM)N/A
Net Income(TTM)-86.57M
Analysts42.86
Price Target12.24 (-12.94%)
Short Float %39.93%
Short Ratio4.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)290.01%
Min EPS beat(2)113.76%
Max EPS beat(2)466.25%
EPS beat(4)3
Avg EPS beat(4)148.54%
Min EPS beat(4)-30.72%
Max EPS beat(4)466.25%
EPS beat(8)6
Avg EPS beat(8)97.31%
EPS beat(12)7
Avg EPS beat(12)68.9%
EPS beat(16)9
Avg EPS beat(16)50.01%
Revenue beat(2)2
Avg Revenue beat(2)22.82%
Min Revenue beat(2)12.99%
Max Revenue beat(2)32.65%
Revenue beat(4)3
Avg Revenue beat(4)24.22%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)70.07%
Revenue beat(8)5
Avg Revenue beat(8)16.46%
Revenue beat(12)9
Avg Revenue beat(12)12.72%
Revenue beat(16)10
Avg Revenue beat(16)8.28%
PT rev (1m)0%
PT rev (3m)5.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)95.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.29
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS10.9
BVpS22.07
TBVpS21.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.12%
ROE -18.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.96%
FCFM N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 2.43
Altman-Z -1.73
F-Score4
WACC7.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.67%
EPS Next Y-104%
EPS Next 2Y-74.93%
EPS Next 3Y385.16%
EPS Next 5Y142.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-21%
Revenue Next Year-19.33%
Revenue Next 2Y-11.01%
Revenue Next 3Y-2.88%
Revenue Next 5Y27.58%
EBIT growth 1Y34.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.85%
EBIT Next 3Y18.07%
EBIT Next 5YN/A
FCF growth 1Y-354.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-337.33%
OCF growth 3YN/A
OCF growth 5YN/A

AMARIN CORP PLC -ADR / AMRN FAQ

What is the fundamental rating for AMRN stock?

ChartMill assigns a fundamental rating of 3 / 10 to AMRN.


What is the valuation status for AMRN stock?

ChartMill assigns a valuation rating of 1 / 10 to AMARIN CORP PLC -ADR (AMRN). This can be considered as Overvalued.


Can you provide the profitability details for AMARIN CORP PLC -ADR?

AMARIN CORP PLC -ADR (AMRN) has a profitability rating of 2 / 10.


What is the earnings growth outlook for AMARIN CORP PLC -ADR?

The Earnings per Share (EPS) of AMARIN CORP PLC -ADR (AMRN) is expected to decline by -104% in the next year.